Find Funding Opportunities

Find Funding Opportunities

Returning 1056 results

Notice of Special Interest (NOSI): Administrative Supplement for Continuity of Biomedical and Behavioral Research Among First-Time Recipients of NIH Research Project Grant Awards

NOT
Friday, January 17, 2020
Monday, March 6, 2023
NOT-OD-20-055

Funding Opportunity Purpose

Notice Special Interest NOSI): Administrative Supplement Continuity Biomedical Behavioral Research Among First-Time Recipients NIH Research Project Grant Awards Notice Number: NOT-OD-20-055 Key Dates Release Date: January 17, 2020 First Available Due Date: March 05, 2020 Expiration Date: March 06, 2023 Related Announcements PA-18-591 Issued Office The Director, National Institutes Health OD)National Eye Institute NEI)National Heart, Lung, Blood Institute NHLBI)National Human Genome Research Institute NHGRI)National Institute Aging NIA)National Institute Alcohol Abuse Alcoholism NIAAA)National Institute Allergy Infectious Diseases NIAID)National Insrtitute Arthritis Musculoskeletal Skin Diseases NIAMS)National Institute Biomedical Imaging Bioengineering NIBIB)National Institute Deafness Other Cormmunication Disorders NIDCD)National Institute Dental Craniofacial Research NIDCR)National Institute Diabetes Digestive Kidney Diseases NIDDK)National Institute Drug Abuse NIDA)National Institute Environmental Health Sciences NIEHS)National Institute General Medical Sciences NIGMS)National Institute Mental Health NIMH)National Institute Neurological Disorders Stroke NINDS)National Institute Nursing Research NINR)National Institute Minority Health Health Disparities NIMHD)National Library Medicine NLM)National Center Complementary Integrative Health NCCIH)National Cancer Institute NCI) applications this funding opportunity announcement should fall within mission the Institutes/Centers. following NIH Offices co-fund applications assigned those Institutes/Centers. Office Behavioral Social Sciences Research OBSSR) Purpose overarching goal this pilot program to enhance retention investigators facing critical life events are transitioning the first renewal their first independent research project grant award to second new NIH research project grant award. Retention the first renewal continuous NIH research project grant support crucial sustaining both ongoing research NIH made investment and retaining diversity the biomedical research workforce. program supports at-risk” investigators identified the NIH Next Generation Researchers Initiative see https://grants.nih.gov/ngri.htm). retention program seeks maintain productivity current first-time recipients eligible independent NIH research project grant awards are dealing a critical life event(s), such they remain competitive the first renewal their award for second research project grant award. retention supplements support transition K award independence, the companion NOSI. Background Investigators, especially women, leave science critical transition stages branching points their career for NIH-supported scientific workforce include transitions post-doctoral training faculty positions Heggeness et al., 2016, Acad Med, doi:10.1097/ACM.0000000000001209 and Nikaj et al., 2019, FASEB Journal, doi:10.1096/fj.201800639) prior obtaining first R01 renewal Hechtman et al., 2018, PNAS, doi:10.1073/pnas.1800615115). rate R01/R01-equiv renewals potential impact the longevity an investigator’s research career Pohlhaus et al., 2011, Acad Med, doi:10.1097/ACM.0b013e31821836ff) remains gender disparity NIH funding should addressed. vulnerable career stages often parallel critical life events commonly contribute faculty attrition. Data NSF demonstrates among racial ethnic groups both biomedical scientists engineers, women far likely men cite family responsibilities a reason leaving work force https://www.nsf.gov/statistics/2017/nsf17310/, especially chart 6B). Pregnancy childbirth particular, appear be significant contributors the underemployment women scientists engineers given pregnancy impact research productivity Cech Blair-Loy 2018, Changing career trajectories new parents STEM; https://www.nsf.gov/statistics/2017/nsf17310/, especially chart 6B). demands childbirth subsequent primary caregiving responsibilities necessitate changes career goals alter researchers career trajectories, depriving scientific workforce an important source talent undermining NIH’s investment promising avenues new research. Retaining investigators this critical transition point protect research investment already via parent NIH award enhance diversity the investigator pool. Budget be eligible, parent award must able receive funds the time the award. administrative supplement budget request limited 1 year. Supplement budget requests cannot exceed 50,000/year direct costs, applicable F&A indirect) cost also requested. Budgets not exceed total direct costs the current parent award. Requests must reflect actual needs the proposed project. Categorical budgets permitted. Awards subject availability funds. Flexible of supplemental funds highly encouraged, may include all inclusive) computational services, supplies, equipment, supported effort additional scientific staff sustain PD/PI’s research during critical life event. Eligible Individuals Program Director/Principal Investigator) PD/PIs the following activity codes eligible the program: DP1, DP2, DP5, R01, R00,  R15, R21, R35, RF1, and U01and have qualifying critical life event. PD/PIs more one independent research project grant award ineligible this supplement. Qualifying Critical Life Events: PD/PI must demonstrate critical life event such childbirth adoption during parent grant project period; primary caregiving responsibilities an ailing spouse, partner, a member the immediate family. circumstances which critical life event pending is expected occur during project period, supplement period be submitted advance the event. supplements parent awards include multiple PDs/PIs, supplement be requested any the PDs/PIs accordance the existing leadership plan on behalf the PD/PI meets eligibility criteria) submitted the grantee institution the parent award. should noted for parent grant for administrative supplement, grantee the institution, the PD/PI. Application Submission Information Supplement requests must submitted accordance the parent program announcement: Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) PA-18-591or subsequent reissued equivalent. Supplement requests must submitted electronically. process Streamlined Submissions using eRA Commons cannot used this initiative. . instructions the SF424 R&R) Application Guide and PA-18-591 must followed, the following additions: Application Due Date(s) – Submission dates vary awarding IC. See Table IC-Specific Information, Requirements Staff Contactsfor details. funding consideration, applicants must include NOT-OD-20-055” without quotation marks) the Agency Routing Identifier field box 4b) the SF424 R&R form. Applications without information box 4b not considered this initiative. Research Strategy section the application limited 6 pages. R&R Project Information form, the Attachments" field: Attach Personal Statement the applicant, including long-term research objectives career goals, justification the supplemental support, a plan return full productivity the end the supplement period. Attach Institutional letter commitment includes details resources mentoring be available the applicant ensure strong productivity the parent grant. letter should also detail institutional commitment the applicant’s return full productivity research career trajectory the end the supplement period. is strongly recommended the applicants contact respective program officers the Institute supporting parent award confirm ahead time the supplement falls within scope the parent award. Further, applicants strongly encouraged notify program contact the Institute supporting parent award See Table IC-Specific Information, Requirements Staff Contacts) that request been submitted response this FOA order facilitate efficient processing the request. Administrative Review Process IC conduct administrative reviews applications submitted their IC. ICs the parent grants support most meritorious applications submitted consideration, pending availability funds. Criteria: the work/activities proposed within scope the parent award? the progress the project prior the life event adequate? the administrative supplement increase preserve likelihood the project succeed, assist candidate complete research project submit timely renewal new research project grant application? there plan the PD/PI return full productivity the end the supplement period? there strong institutional commitment e.g., protected time, policies, programs, other strategies) ensure the PD/PI maintains his/her research project independent research trajectory? Inquiries Please direct inquiries to: Melissa Ghim, PhD Office Research Women’s Health ORWH) Division Program Coordination, Planning, Strategic Initiatives DPCPSI) Telephone: 301-496-7853 Email: melissa.ghim@nih.gov

Notice of Correction to Open Date in RFA-NS-19-043 "BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)"

NOT
Thursday, January 16, 2020
Sunday, January 1, 2023
NOT-NS-20-037

Funding Opportunity Purpose

Notice Correction Open Date RFA-NS-19-043 BRAIN Initiative Advanced Postdoctoral Career Transition Award Promote Diversity K99/R00 Independent Clinical Trial Allowed)" Notice Number: NOT-NS-20-037 Key Dates Release Date: Janaury 16, 2020 Related Announcements RFA-NS-19-043 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform interested applicants a correction the Open Date Earliest Submission Date) RFA-NS-19-043 "BRAIN Initiative Advanced Postdoctoral Career Transition Award Promote Diversity K99/R00 Independent Clinical Trial Allowed)". Open Date Earliest Submission Date) January 9, 2020. Changes the FOA shown Bold Italics below. Currently Reads: Part 1. Overview Information Key Dates Open Date Earliest Submission Date) January 9, 2022 Modified Read: Part 1. Overview Information Key Dates Open Date Earliest Submission Date) January 9, 2020 other aspects this FOA remain same. Inquiries Please direct inquiries to: Michelle Jones-London, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-451-7966 Email: BRAINDIVERSITYK99R00@nih.gov

HEAL Initiative: Back Pain Consortium (BACPAC) Research Program Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions.

NOT
Wednesday, January 15, 2020
Saturday, March 14, 2020
NOT-AR-20-016

Funding Opportunity Purpose

HEAL Initiative: Back Pain Consortium BACPAC) Research Program Notice Special Interest NOSI) regarding Availability Urgent Competitive Revisions. Notice Number: NOT-AR-20-016 Key Dates Release Date: January 15, 2020 First Available Due Date: March 13, 2020 Expiration Date: March 14, 2020 Related Announcements PA-18-935NOT-AR-20-015 Issued National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Drug Abuse NIDA) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) National Institute Minority Health Health Disparities NIMHD) National Center Complementary Integrative Health NCCIH) National Center Advancing Translational Sciences NCATS) applications this funding opportunity announcement should fall within mission the Institutes/Centers. following NIH Offices co-fund applications assigned those Institutes/Centers. Office Behavioral Social Sciences Research OBSSR) Office Research Women's Health ORWH) Purpose Notice Special Interest NOSI) calls research pain management the context opioid or opioid disorder OUD). particular, NIAMS interested providing data-driven evidence regarding effective mechanisms reducing reliance opioids while maintaining quality life. Funds Competitive Revisions active grants available part the NIH HEAL Helping End Addiction Long-termSM) Initiative awardees operate within Back Pain Consortium BACPAC) Research Program, part the NIH HEAL InitiativeSM. Investigators active grants the area chronic pain and/or addiction encouraged apply. award two phases, one-year Planning Phase a to three year Research Project Phase. Background Back Pain the major form chronic pain among adults worldwide the most common, non-cancer reason opioid prescription the US. NIH HEAL InitiativeSM is trans-NIH initiative the aims improving treatments opioid misuse addiction; enhancing pain management, understanding biological underpinnings chronic pain accelerating discovery development non-addictive treatments pain. Back Pain Consortium BACPAC) Research Program, part the NIH HEAL InitiativeSM, provides platform research the intersection pain management opioid or opioid disorder OUD). BACPAC a patient-centric translational research initiative, is taking biopsychosocial approach the study chronic low back pain cLBP) the need more effective personalized treatments. Research Objectives order effectively reduce reliance opioids the treatment chronic low back pain while maintaining quality life, NIAMS encouraging submission applications Competitive Revisions active grants provide evidence-based data inform clinical practice guidelines. Research areas interest include: Project Planning Phase - are key questions providers patients with respect opioid for managing chronic pain? Questions interest might patient-centric and/or provider-focused, e.g., is appropriate prescribe opioids chronic pain; someone already taking opioids pain management are most effective means reducing dependence; alternatives exist? Research Project Phase - Investigators should propose strategies test most effective means managing pain while reducing dependence opioids the intent informing clinical practice. Award Information NIAMS intends commit 320,000 FY2020, Planning Phase, 800,000 year the Research Project Phase, FY2021 through FY2023, fund to awards. Budget research project length should reflect project needs, the parent grant must active throughout duration the Competitive Revision. Awardees expected share data resources consistent the guidelines policies the NIH, NIH HEAL InitiativeSM, as developed the Steering Committee the BACPAC Research Program. Adherence these guidelines policies be required the terms conditions award. Application Submission Information Applications response this NOSI must submitted using following target funding opportunity: PA-18-935 Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional) Eligible activity codes applications to PA-18-935 are dependent upon target Institute, Center, Office ICO). Table 1 lists activity codes will accepted each participating ICO. Table 1: Eligible Activity Codes Participating ICO Activity Code NIAMS NIBIB NINR NIMHD NICHD NIAAA NCATS NCCIH NIDA NINDS DP1 NIH Director’s Pioneer Award Yes Yes No No Yes Yes Yes P01 Research Program Projects No No No Yes Yes P41 Research Program Projects Centers Yes No No No No P50 Specialized Center Yes No No Yes Yes Yes R01 Research Project Grant Yes Yes Yes Yes Yes Yes Yes Yes Yes R35 Outstanding Investigator Award No No No No Yes R61 Phase 1 Exploratory/Developmental Grant Yes No No No Yes Yes Yes U01 Research Project – Cooperative Agreements Yes Yes Yes No Yes Yes Yes Yes Yes U18 Research Demonstration- Cooperative Agreements Yes Yes No No No Yes Yes U19 Research Program Cooperative Agreement Yes No Yes No Yes Yes U24 Resource-Related Research Projects – Cooperative Agreements Yes Yes No Yes Yes Yes Yes U54 Specialized Center- Cooperative Agreements Yes Yes Yes No Yes Yes Yes U2C Resource-Related Research Multi-Component Projects Centers Cooperative Agreements No No No No Yes UF1 Multi-Year Funded Research Project Cooperative Agreement No No No No Yes UG1 Clinical Research Cooperative Agreements-Single Project Yes No No No Yes Yes UH3 Exploratory/Developmental Phased Award Cooperative Agreement Yes Yes No No Yes Yes Yes Yes UM1 Multi-Component Research Project Cooperative Agreements No No No No Yes All instructions the SF424 R&R) Application Guide and PA-18-935 must followed, the following additions: Research Strategy section the application limited 12 pages. award project period the Competitive Revision must three four years, one year the Planning Phase two three years the Research Project Phase. deadline applications is March 13, 2020 5:00 PM local time of applicant organization. NOSI expires March 14, 2020. application submitted response this NOSI is received March 14, 2020 later, be withdrawn. Applications should must submitted PA-18-935, ldquo;Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement – Clinical Trial Optional)" using application forms package the Competition ID ldquo;NOT-AR-20-016-FORMS-E” IMPORTANT: funding consideration, applicants must designate NOT-AR-20-016 in Agency Routing Identifier field Box 4b) the SF424 R&R) Form. Applications without information Box 4b not considered this initiative. Applications non-responsive the terms this Notice be be considered this initiative. Review criteria, addition those described PA-18-935, include following: Does PI(s)/PD(s) expertise pain management and/or addiction appropriate the study low back pain opioid use? Does application propose engage patients, providers, relevant stakeholders identifying key questions regarding pain management opioid use, curtailment, alternatives opioids? successful, does application the potential inform clinical decision making? the PI(s)/PD(s) considered their work might interface or avail the BACPAC research program? Investigators planning submit application response the NOSI strongly encouraged contact appropriate Institute Center contact listed the NOSI discuss proposed project the context the parent award. Questions specific this NOSI should sent to bacpac-nih@mail.nih.gov. Applications nonresponsive terms this NOSI be be considered the NOSI initiative. nbsp; Inquiries Please direct inquiries to: Scientific/Research Contact(s) Leslie K. Derr, Ph.D National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Telephone: 301-402-4735 Email: derrl@mail.nih.gov Laura Kwako, PhDNational Institute Alcohol Abuse Alcoholism NIAAA) Telephone: 301-451-8507 Email: laura.kwako@nih.gov Michael B. Wolfson, PhD National Institute Biomedical Imaging Bioengineering NIBIB) Telephone: 301-451-4778 Email: Michael.Wolfson@nih.gov Susan Marden PhD RN Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) Telephone: 301-435-6838 Email: mardens@mail.nih.gov Shelley Su, PhD National Institute Drug Abuse NIDA) Telephone: 301-402-3869 Email: shelley.su@nih.gov Benyam Hailu, MD, MPH National Institute Minority Health Health Disparities NIMHD) Telephone: 301-594-8696 Email: Benyam.Hailu@nih.gov Michael L. Oshinsky, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-9964 Email: michael.oshinsky@nih.gov D.P. Mohapatra, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-9964 Email: dp.mohapatra@nih.gov Lois A. Tully, PhD National Institute Nursing Research NINR) Telephone: 301-594-5968 Email: tullyla@mail.nih.gov Lanay M. Mudd, PhD National Center Complementary Integrative Health NCCIH) Telephone: 301-594-9346 Email: Lanay.mudd@nih.gov Jane Atkinson, DDS National Center Advancing Translational Sciences NCATS) Telephone: 301-827-6031 Email: jatkinso@mail.nih.gov Lisa Begg, Dr.P.H., R.N.Office Research Women’s Health ORWH) Telephone: 301/496-3975 E-mail: beggl@od.nih.gov

Notice of Data Sharing Policy for Autism Data

NOT
Monday, January 13, 2020
Sunday, January 1, 2023
NOT-MH-20-010

Funding Opportunity Purpose

Notice Data Sharing Policy Autism Data Notice Number: NOT-MH-20-010 Key Dates Release Date: January 13, 2020 Related Announcements NOT-MH-09-005 NOT-MH-19-033 Issued National Institute Mental Health NIMH) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Environmental Health Sciences NIEHS) National Institute Neurological Disorders Stroke NINDS) Purpose Widespread data sharing research communities adds significant value research accelerates pace discovery. NIMH Data Archive https://nda.nih.gov/, NDA) been established enable responsible sharing use data collected and human subjects the entire research community. Consistent authorities under 21st Century Cures Act, researchers are conducting autism research involving human subjects funded the Institutes participating this Notice required deposit raw analyzed data including, not limited to, clinical, genomic, imaging, phenotypic data) the NDA infrastructure. Unless NIH stipulates otherwise during negotiation the terms conditions a grant award, Notice applies all grant applications awards involve human subject research related autism are submitted after September 1, 2020 through Funding Opportunity Announcements FOAs)in the institutes participatingin notice also participants the FOA. Investigators applications assigned NIMH abide the data sharing timeline published NOT-MH-19-033. Notice does apply following types applications: Fellowship F) Research Career Development K) Training T) Small Business SBIR/STTR) Small Grants R03) Education R25) Notice updates replaces NOT-MH-09-005. Data were previously stored the National Database Autism Research referred in Notice been incorporated the NIMH Data Archive NDA). Non-NIH funded researchers human subjects data relevant autism welcome deposit data they willing adhere the archive’s data sharing terms conditions https://nda.nih.gov/contribute/contribute-data.html). data archive a rich source data can used a variety ways, including development preliminary data support application. Investigators strongly encouraged explore data the data dictionaries are available before submitting application. Resource Sharing Expectations Grant Applications NDA provides infrastructure support enable autism researchers deposit data to share data the research community. Prior applying a grant, investigators should review planning section the web site https://nda.nih.gov/contribute/contribute-data.html). Applicants strongly encouraged use clinical phenotypic data collection instruments/data dictionaries have already defined rather create new versions those data dictionaries. are several required data collection instruments, mostly related demographic sample information, must used all researchers data harmonization purposes https://nda.nih.gov/standards.html). Applicants should also plan collect data needed generate global unique identifiers GUIDs) each study subject https://nda.nih.gov/contribute/harmonization-standards.html#guid). Informed consent documents should describe study data be shared NDA the research community https://nda.nih.gov/contribute/contribute-data.html#infocon). necessary funds submitting data the NDA should included the requested budget. cost estimator https://nda.nih.gov/ndarpublicweb/Documents/NDA_Data_Submission_Costs.xlsx) available facilitate calculation these costs. Post-Award Data Management Data funded awards be submitted NDA every 6 months. Within 6 months the original award, awardees provide Data Submission Agreement signed the principal investigator an institutional business official. most cases, single NDA Collection containing data associated each grant award be established. Submitting data this Collection distinct sharing data the research community. Submitted data generally held a private enclave open only the awardee until data shared the research community. Data submission requires data undergo validations other quality control checks the data deposited. Performing checks improves reliability reproducibility the data. While general data sharing expectation for data be submitted every 6 months, researchers strongly encouraged use NDA validation tool https://nda.nih.gov/vt/) much frequently. Awardees strongly encouraged submit full study clinical trial protocol one exists, additional information each Collection. Data be shared the research community papers using data been accepted publication at end the award period including first cost extension), whichever occurs sooner. Applicants encouraged share basic demographic raw baseline data shortly after data submission encourage collaborations the research community. addition submitting data associated a grant award they collected, researchers expected separately submit NDA specific data was used each resulting publication creating NDA Study. NDA assigns digital object identifier each study, studies should created prior publication will only shared papers accepted publication. Creation these studies encourage rigor reproducibility https://nda.nih.gov/training/modules/study.html). Inquiries Please direct inquiries to: technical assistance data submission, please contact NDA help desk NDAHelp@mail.nih.gov). other inquiries please contact: Gregory K. Farber, Ph.D. National Institute Mental Health NIMH) Telephone: 301-435-0778 Email: farberg@mail.nih.gov

Addition of SBIR Direct-to-Phase II Program to NINDS RFA-NS-18-012, "Translational Neural Devices (U44 Clinical Trial Required)"

NOT
Monday, January 6, 2020
Sunday, January 1, 2023
NOT-NS-20-034

Funding Opportunity Purpose

Addition SBIR Direct-to-Phase II Program NINDS RFA-NS-18-012, Translational Neural Devices U44 Clinical Trial Required)" Notice Number: NOT-NS-20-034 Key Dates Release Date: January 6, 2020 Related Announcements RFA-NS-18-012 Issued National Institute Neurological Disorders Stroke NINDS) Purpose Section 5106 the SBIR/STTR Reauthorization Act 2011 authorized NIH ‘issue Phase II award a small business concern did receive Phase award that research/research & development'. phase flexbility' called ‘Direct-to-Phase II’ SBIR award. original authority this provision expired 9/30/2017. Recent legislation P.L. 115-232 re-instated SBIR Direct Phase II provision through Fiscal Year 2022. SBIR Direct-to-Phase II authority not available the STTR program not available the CDC, FDA, ACL SBIR progams. such, NIH re-implementing SBIR Direct-to-Phase II program. prior program specific SBIR Direct-to-Phase II funding opportunity announcements FOAs). transition FORMS-E earlier year allows NIH track SBIR Direct-to-Phase II applications the Application level, there a new check-box the SBIR/STTR Information Form Direct Phase II. a result this, NIH does need issue separate SBIR Direct-to-Phase II FOAs before, can offer Direct-to-Phase II an allowable Application Type any SBIR FOA. NINDS therefore amending RFA-NS-18-012 allow SBIR Direct-to-Phase II submissions NIH strongly encourages small businesses contact appropriate Institute Center early their application planning process ensure technology of priority the Institute/Center following sections RFA-NS-18-012 changed follows: Part 2, Section II. Award Information Currently Reads: Application Types Allowed New Fast-Track) Resubmission Fast-Track) Revision Fast-Track) OER Glossary the SF424 R&R) SBIR/STTR Application Guide provide details these application types. Modified Read: Application Types Allowed New Fast-Track) New Phase II - Direct Phase II) Resubmission Direct Phase II, Fast-Track) Revision Direct Phase II, Fast-Track) OER Glossary the SF424 R&R) SBIR/STTR Application Guide provide details these application types. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Emily Caporello, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1779 Email: Emily.caporello@nih.gov Nick Langhals, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1779 Email: nick.langhals@nih.gov

Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

NOT
Monday, January 6, 2020
Sunday, January 1, 2023
NOT-NS-20-032

Funding Opportunity Purpose

Notice Intent Publish Funding Opportunity Announcement Blueprint Neurotherapeutics Network BPN): Small Molecule Drug Discovery Development Disorders the Nervous System U44 Clinical Trial Optional) Notice Number: NOT-NS-20-032 Key Dates Release Date: January 06, 2020 Estimated Publication Date Funding Opportunity Announcement: February 08, 2020 First Estimated Application Due Date: August 11, 2020 Earliest Estimated Award Date: February 16, 2021 Earliest Estimated Start Date: April 01, 2021 Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS) Purpose NIH announces intention reissue PAR-18-541 SBIR-eligible small businesses seeking support the Blueprint Neurotherapeutics Network BPN). Applicants encouraged utilize customized set contract resources, consultants the Blueprint Neurotherapeutics Network BPN) help advance neuroscience-focused drug discovery development projects the clinic. Notice provided allow potential applicants sufficient time develop meaningful collaborations responsive projects. FOA utilize U44 activity code. Details the planned FOA provided below. FOA expected be published February 2020 an expected application due date August 2020. Research Initiative Details facilitate drug discovery development the neuroscience community, NIH Blueprint Neuroscience Research http://neuroscienceblueprint.nih.gov/) established Blueprint Neurotherapeutics Network BPN), collection contract service providers consultants extensive industry experience the areas pharmacology, medicinal chemistry, pharmacokinetics, toxicology, GMP synthesis, formulation development, Phase clinical safety testing. list consultants contract service providers be viewed http://neuroscienceblueprint.nih.gov/bpdrugs/bpn.htm. reissued Funding Opportunity Announcement FOA) encourage applications SBIR-eligible small businesses seeking funding through Fast-Track phased U44 cooperative agreement mechanism help advance drug discovery development projects the clinic. Applicants be encouraged build customized utilization BPN services their applications. be eligible the BPN, applicant must well-validated bioactive compound(s) hand; BPN does support screening hit compounds. Projects enter BPN during Discovery Development may seek support through phase I/first-in-human testing. Discovery involves iterative medicinal chemistry improve potency ADMET properties compounds, toward goal identifying clinical candidate. During Development, clinical candidate undergoes preclinical toxicology testing required an IND manufacturing, ultimately advancing phase I/first-in-human testing. BPN Development activities include chemical manufacturing controls CMC), formulation development, toxicology studies, regulatory support, phase I/first-in-human testing. NIH assemble customized Lead Development Team each project accepted the program. Lead Development Team typically be co-chaired the Program Director/Principal Investigator PD/PI) a consultant extensive industry expertise identified supported the NIH. Lead Development Team also include members the PD/PI's team, NIH-hired consultants additional expertise, NIH staff. Lead Development Team plan coordinate work supported the cooperative agreement award conducted BPN contractors. Discovery projects begin a U44 Phase award up two years. first 6-12 months be used complete any studies required meet Discovery Development entry criteria to engage Lead Development Team establishing detailed research plan, go/no-go milestones, all subsequent work. Applicants strongly encouraged consult NIH program staff plans an application being developed. Consultations include conference calls NIH program staff webinars. Early contact provides opportunity NIH program staff discuss program scope, entry criteria, goals, to provide information guidance how develop competitive application. It's recommended applicants contact NIH staff least 8 weeks before receipt date. additional information the BPN, please http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm Funding Information Estimated Total Funding Expected Number Awards TBD Estimated Award Ceiling Primary CFDA Numbers TBD nbsp; Anticipated Eligible Organizations Public/State Controlled Institution Higher Education Private Institution Higher Education Nonprofit 501(c)(3) IRS Status than Institution Higher Education) Small Business For-Profit Organization than Small Business) State Government Indian/Native American Tribal Government Federally Recognized) County governments Independent school districts Public housing authorities/Indian housing authorities Indian/Native American Tribally Designated Organization Native American tribal organizations than Federally recognized tribal governments) U.S. Territory Possession Indian/Native American Tribal Government than Federally Recognized) Non-domestic non-U.S.) Entity Foreign Organization) Regional Organization Applications not being solicited this time. Inquiries Please direct inquiries to: Charles Cywin, PhD National Institute Neurological Disorders Stroke NINDS) 301-496-1779 Email: cywincl@ninds.nih.gov

Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

NOT
Monday, January 6, 2020
Sunday, January 1, 2023
NOT-NS-20-033

Funding Opportunity Purpose

Notice Intent Publish Funding Opportunity Announcement Blueprint Neurotherapeutics Network BPN): Small Molecule Drug Discovery Development Disorders the Nervous System UG3/UH3 Clinical Trial Optional) Notice Number: NOT-NS-20-033 Key Dates Release Date: January 06, 2020 Estimated Publication Date Funding Opportunity Announcement: February 11, 2020 First Estimated Application Due Date: August 08, 2020 Earliest Estimated Award Date: February 01, 2021 Earliest Estimated Start Date: April 01, 2021 Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS) Purpose NIH announces intention reissue PAR-18-546 investigators seeking support the Blueprint Neurotherapeutics BPN) Network. Applicants be encouraged utilize customized set contract resources, consultants the BPN Network help advance neuroscience-focused drug discovery development projects the clinic. Notice provided allow potential applicants sufficient time develop meaningful collaborations responsive projects. FOA utilize UG3/UH3 activity code. Details the planned FOA provided below. FOA expected be published February 2020 an expected application due date August 2020. Research Initiative Details facilitate drug discovery development the neuroscience community, NIH Blueprint Neuroscience Research http://neuroscienceblueprint.nih.gov/) established Blueprint Neurotherapeutics BPN) Network, collection contract service providers consultants extensive industry experience the areas pharmacology, medicinal chemistry, pharmacokinetics, toxicology, GMP synthesis, formulation development, Phase clinical safety testing. list consultants contract service providers be viewed http://neuroscienceblueprint.nih.gov/bpdrugs/bpn.htm. planned reissue Funding Opportunity Announcement FOA) encourage applications investigators seeking funding through UG3/UH3 phased cooperative agreement mechanism help advance drug discovery development projects the clinic. Applicants be encouraged build customized utilization BPN services their applications. be eligible the BPN, applicant must well-validated bioactive compound(s) hand; BPN does support screening hit compounds. Projects enter BPN during Discovery Development may seek support through phase I/first-in-human testing. Discovery involves iterative medicinal chemistry improve potency ADMET properties compounds, toward goal identifying clinical candidate. During Development, clinical candidate undergoes preclinical toxicology testing required an IND manufacturing, ultimately advancing phase I/first-in-human testing. BPN Development activities include chemical manufacturing controls CMC), formulation development, toxicology studies, regulatory support, phase I/first-in-human testing. NIH assemble customized Lead Development Team each project accepted the program. Lead Development Team typically be co-chaired the Program Director/Principal Investigator PD/PI) a consultant extensive industry expertise identified supported the NIH. Lead Development Team also include members the PD/PI's team, NIH-hired consultants additional expertise, NIH staff. Lead Development Team plan coordinate work supported the cooperative agreement award conducted BPN contractors. projects enter BPN begin a preparatory phase UG3) up one year, can used complete any studies required meet Discovery Development entry criteria to engage Lead Development Team establishing detailed research plan, go/no-go milestones, all subsequent work. Applicants strongly encouraged consult NIH program staff plans an application being developed. Consultations include conference calls NIH program staff webinars. Early contact provides opportunity NIH program staff discuss program scope, entry criteria, goals, to provide information guidance how develop competitive application. It's recommended applicants contact NIH staff least 8 weeks before receipt date. additional information the BPN, please http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm Funding Information Estimated Total Funding Expected Number Awards TBD Estimated Award Ceiling Primary CFDA Numbers TBD Anticipated Eligible Organizations Public/State Controlled Institution Higher Education Private Institution Higher Education Nonprofit 501(c)(3) IRS Status than Institution Higher Education) Small Business For-Profit Organization than Small Business) State Government Indian/Native American Tribal Government Federally Recognized) County governments Independent school districts Public housing authorities/Indian housing authorities Indian/Native American Tribally Designated Organization Native American tribal organizations than Federally recognized tribal governments) U.S. Territory Possession Indian/Native American Tribal Government than Federally Recognized) Non-domestic non-U.S.) Entity Foreign Organization) Regional Organization Applications not being solicited this time. Inquiries Please direct inquiries to: Charles Cywin, PhD National Institute Neurological Disorders Stroke NINDS) 301-496-1779 Email: cywincl@ninds.nih.gov

Notice of Special Interest: Administrative Supplements for Existing NIH Countermeasures Against Chemical Threats (CounterACT) Program Research Grants and Cooperative Agreement Awards

NOT
Monday, January 6, 2020
Tuesday, August 4, 2020
333
NOT-NS-20-029

Funding Opportunity Purpose

Notice Special Interest: Administrative Supplements Existing NIH Countermeasures Against Chemical Threats CounterACT) Program Research Grants Cooperative Agreement Awards Notice Number: NOT-NS-20-029 Key Dates Release Date: January 6, 2020 First Available Due Date: August 03, 2020 Expiration Date: August 04, 2020 Related Announcements PA-18-591 NOT-NS-20-030 Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose NIH inviting administrative supplement applications provide additional funds active CounterACT research grants cooperative agreement projects support activities such new collaborations pilot studies were unanticipated the time the new competing continuation application submitted. proposed activities must within original research scope the parent award. Supplemental funding includes direct costs well associated facilities administrative costs. supplement project start any time during budget period must end the last day the budget period. parent award not in terminal no-cost extension going a no-cost extension FY2020. Application budgets limited 75,000 total costs must reflect actual needs the proposed project. Only parent CounterACT research grant cooperative agreement awards funded through following FOAs any reissues these announcements) eligible request supplemental funding under NOSI: PAR-13-208: Countermeasures Against Chemical Threats CounterACT) Cooperative Research Projects U01) PAR-15-146; PAR-16-329; PAR-18-657: Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional) PAR-16-330: Countermeasures Against Chemical Threats CounterACT): Identification Therapeutic Lead Compounds U01 Clinical Trial Allowed) PAR-16-331: Countermeasures Against Chemical Threats CounterACT): Optimization Therapeutic Lead Compounds U01 Clinical Trial Optional) PAR-18-721: Countermeasures Against Chemical Threats CounterACT) Exploratory/Developmental Projects Translational Research R21 Clinical Trial Allowed) Scope Interest overall goal the NIH Countermeasures Against Chemical Threats CounterACT) program to support research development therapeutics can reduce mortality morbidity the event the release chemical threat agents. Chemical threat agents toxic compounds could released a deliberate terrorist attack against civilians, by accidental natural disaster causing mass casualties. include chemical warfare agents e.g., sarin, chlorine, sulfur mustard), toxic industrial chemicals e.g., cyanide, hydrogen sulfide, phosgene), pesticides e.g., parathion, brodifacoum), pharmaceutical-based agents e.g., opioids) other chemicals. Applications proposing research chemical threats are of interest the program not considered funding. research related opioid threats being proposed, NOT-NS-18-019 a description research supported the NIH CounterACT program. Examples topics interest include, are limited to: Facilitating collaborations fellow awardees within CounterACT community Identify and/or recruit new resources such investigators additional expertise, industry partner, research tools, systems, assays enhance outcomes the parent award Limited, pilot studies establish proof-of-principle approaches Investigators planning submit application response this NOSI strongly advised contact discuss proposed research/aims the Program Officer their parent CounterACT award well advance the receipt deadline better determine appropriateness relevance the supplement project Application Submission Information Applications this initiative must submitted using following opportunity its subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) instructions the SF424 R&R) Application Guide PA-18-591 must followed, the following additions Research Strategy part the application, summarize scope the parent supplemental projects describe proposed aims research strategy the new study. Clearly state the supplemental efforts fit the scope the parent award. research strategy should clearly demonstrate the new collaboration(s), resource(s), and/or studies benefit parent award why those otherwise be feasible either within currently funded efforts by rebudgeting funds. Applicants the program urged consider directly address elements rigor reproducibility described NOT-OD-15-103 their experimental design. Administrative Evaluation Criteria the proposed supplemental project outcomes relevant the NIH CounterACT program mission goals? the work proposed within scope the active parent award? Does proposed research/scientific team possess expertise conduct achieve goals the supplemental study? Does supplemental proposal include well-described, rigorous scientific approach? the project yield significant preliminary data support more advanced drug discovery development efforts? the scope budget reasonable the proposed studies? Letters Support Applicants must include letter appropriate institutional biosafety officials indicating studies deemed safe research personnel the environment. formal letter support must provided all newly proposed collaborative, consultative, and/or contract arrangements. Application Due Date(s) – August 3,2020, 5:00 PM local time applicant organization. funding consideration, applicants must include “NOT-NS-20-029” without quotation marks) the Agency Routing Identifier field box 4b) the SF424 R&R form. Applications without information box 4b not considered this initiative. Requests be one year support only. Research Strategy section the application limited 6 pages. Only existing awardees CounterACT program eligible apply. process Streamlined Submissions using eRA Commons cannot used this initiative. Applicants strongly encouraged notify CounterACT Program Officer the parent award a request been submitted response this FOA order facilitate efficient processing the request. application budget cannot exceed 75,000 total costs must reflect actual needs the project. Inquiries Please direct inquiries related the overall NIH CounterACT Program and/or parent awards managed the National Institutes Neurological Disorders Stroke NINDS) to: David A. Jett, PhD Telephone: 301-496-6035 Email: jettd@nih.gov Shardell M. Spriggs, PhD Telephone: 301-443-8189 Email: shardell.spriggs@nih.gov parent awards managed the National Institute Arthritis Musculoskeletal Skin Diseases NIAMS): Hung Tseng, Ph.D. Telephone: 301-594-5032 Email: tsengh@mail.nih.gov parent awards managed the National Eye Institute NEI): Houmam Araj, Ph.D. Telephone: 301-451-2020 Email: arajh@nei.nih.gov parent awards managed the National Institute Environmental Health Sciences NIEHS): Srikanth S. Nadadur, Ph.D. Telephone: 984-287-3296 Email: nadadurs@niehs.nih.gov parent awards managed the National Institute Drug Abuse NIDA): Kristopher Bough, Ph.D. Telephone: 301-443-9800 Email: boughk@nih.gov

Notice of Special Interest: Administrative Supplements to Promote and Expand into the Research and Development of Medical Countermeasures Against Chemical Threats

NOT
Monday, January 6, 2020
Tuesday, August 4, 2020
333
NOT-NS-20-030

Funding Opportunity Purpose

Notice Special Interest: Administrative Supplements Promote Expand the Research Development Medical Countermeasures Against Chemical Threats Notice Number: NOT-NS-20-030 Key Dates Release Date: January 6, 2020 First Available Due Date: February 03, 2020 Expiration Date: August 04, 2020 Related Announcements PA-18-591 NOT-NS-20-029 Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose NIH inviting administrative supplement applications existing awards are currently focused developing medical countermeasures MCMs) against chemical threats allow to expand research focus this critical field. Supplemental funding includes direct costs well associated facilities administrative costs. supplement project start any time during budget period must end the last day the budget period. parent award not in terminal no-cost extension. Application budgets limited no than amount the current award 125,000 total costs whichever lower) must reflect actual needs the proposed project. Scope Interest overall goal the NIH Countermeasures Against Chemical Threats CounterACT) program to support research development therapeutics can reduce mortality morbidity the event the release chemical threat agents. Chemical threat agents toxic compounds could released a deliberate terrorist attack against civilians, by accidental natural disaster causing mass casualties. include chemical warfare agents e.g., sarin, chlorine, sulfur mustard), toxic industrial chemicals e.g., cyanide, hydrogen sulfide, phosgene), pesticides e.g., parathion, brodifacoum), pharmaceutical-based agents e.g., opioids) other chemicals. research related opioid threats being proposed, NOT-NS-18-019 a description research supported the NIH CounterACT program. scope research will supported this NOSI should consistent the following currently published funding opportunity announcements, PAR-18-721, PAR-19-030, PAR-19-040, including basic translational research through preclinical studies. view list currently funded projects, please visit our webpage, CounterACT Research Network Funded Investigators. Examples topics chemical agents interest include, are limited to: Pulmonary Agents Chlorine Phosgene): Development MCMs prevent treat lung damage including pulmonary edema fibrosis) resulting after exposure Pharmaceutical-based Agents Synthetic Opioids): Development MCMs treat life-threatening respiratory depression caused opioid intoxication. post-exposure treatments should quick-acting effective against variety opioids, e.g., fentanyl, carfentanil. NOT-NS-18-019 more details Vesicants Sulfur Mustard Lewisite): Development MCMs mitigate acute and/or long-term injuries resulting exposure the skin, eyes, mucous membranes vesicating agents. Specific areas interest include treating corneal neovascularization, fibrosis, mustard gas keratopathy. Cellular Respiration/Blood Agents Cyanide): Development MCMs treat acute poisoning. Antidotes should rapidly effective easily administered first responders Nerve Agents Organophosphorus OP) Pesticides: Development MCMs treat seizures either before after become refractory treatment benzodiazepines therapeutics promote neuronal survival other persistent effects after seizure termination. the federal monograph, Sarin: Potential Long-term Neurological Effects. are chemicals interest addition those listed above, Investigators planning submit application response this NOSI strongly advised contact discuss proposed research/aims the Program Officer their parent award the CounterACT Program Officer listed below) most relevant the supplement project well advance the receipt deadline determine responsiveness, programmatic interest, relevance. Applications propose research chemical threats are of interest the program not considered funding. Application Submission Information Applications this initiative must submitted using following opportunity its subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) instructions the SF424 R&R) Application Guide PA-18-591 must followed, the following additions Research Strategy part the application, include abstract the proposed research shows relevance developing chemical medical countermeasures. Summarize scope the parent supplemental projects describe proposed aims research strategy the new study. Clearly state the supplemental efforts fit the scope the parent grant. Applicants the program urged consider directly address elements rigor reproducibility described NOT-OD-15-103 their experimental design. Administrative Evaluation Criteria the proposed supplemental project outcomes relevant the NIH CounterACT program mission goals? the work proposed within scope the active parent award? Does proposed research/scientific team possess expertise conduct achieve goals the supplemental study? Does supplemental proposal include well-described, rigorous scientific approach? the project yield significant preliminary data support more advanced drug discovery development efforts? the scope budget reasonable the proposed studies Letters Support Applicants must include letter appropriate institutional biosafety officials indicating studies deemed safe research personnel the environment. formal letter support must also provided all newly proposed collaborative, consultative, and/or contract arrangements. Application Due Date(s) – February 3, 2020, April 1, 2020, June 1, 2020, August 3, 2020, 5:00 PM local time applicant organization. funding consideration, applicants must include NOT-NS-20-030” without quotation marks) the Agency Routing Identifier field box 4b) the SF424 R&R form. Applications without information box 4b not considered this initiative. Requests be one year support only. Research Strategy section the application limited 6 pages. process Streamlined Submissions using eRA Commons cannot used this initiative. Applicants strongly encouraged notify program contact the Institute supporting parent award the CounterACT Program Officer listed below) most relevant the supplemental project a request been submitted response this FOA order facilitate efficient processing the request. application budget cannot exceed 125,000 total costs. Inquiries Please direct inquiries related the overall NIH CounterACT Program, neurological injury metabolic/blood research to: David A. Jett, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-6035 Email: jettd@nih.gov Shardell M. Spriggs, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-443-8189 Email: shardell.spriggs@nih.gov questions related dermal/vesicant-induced injuries: Hung Tseng, Ph.D. National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Telephone: 301-594-5032 Email: tsengh@mail.nih.gov questions related ocular injury research: Houmam Araj, Ph.D. National Eye Institute NEI) Telephone: 301-451-2020 Email: arajh@nei.nih.gov questions related pulmonary injury research: Srikanth S. Nadadur, Ph.D. National Institute Environmental Health Sciences NIEHS) Telephone: 919-541-5327 Email: nadadurs@niehs.nih.gov questions related pharmaceutical based agents: Kristopher Bough, Ph.D. National Institute Drug Abuse NIDA) Telephone: 301-443-9800 Email: boughk@nih.gov

Notice of Special Interest: Countermeasures Against Chemical Threats (CounterACT) U54 Centers of Excellence will only support targeted chemical threats of interest

NOT
Monday, January 6, 2020
Thursday, September 10, 2020
U54
NOT-NS-20-031

Funding Opportunity Purpose

Notice Special Interest: Countermeasures Against Chemical Threats CounterACT) U54 Centers Excellence only support targeted chemical threats interest Notice Number: NOT-NS-20-031 Key Dates Release Date: 01/06/2020 First Available Due Date: September 09, 2020 Expiration Date: September 10, 2020 Related Announcements PAR-18-657 Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose NIH Countermeasures Against Chemical Threats CounterACT) program supports research development therapeutics can reduce mortality morbidity the event the release chemical threat agents. important component the CounterACT research network the U54 Research Centers Excellence. U54 Centers designed support three more projects scientific cores having unifying well-defined goal problem area research synergistically produce rigorous interdisciplinary research the highest quality. is expectation support interrelated projects collaborating investigators yield results beyond those achievable each project pursued separately without formal interaction among participating investigators. more information the CounterACT Program, please visit our website. view list currently funded projects, please visit our webpage, CounterACT Research Network Funded Investigators. NIH CounterACT program issuing NOSI provide chemical threat agents will supported grant applications the September 9, 2020 receipt date PAR-18-657 U54 Centers Excellence. only chemical agents will supported the U54 program are: Blood/Metabolic Agents: hydrogen cyanide, potassium cyanide sodium cyanide Organophosphorus OP) Chemical Warfare Agents Pesticides Opioids: carfentanil, fentanyl related analogs, NOT-NS-18-019 Pulmonary Agents: chlorine phosgene Vesicants: sulfur mustard lewisite Applicants strongly encouraged contact CounterACT Program Staff listed the parent funding opportunity announcement PAR-18-657) determine their proposed threat agent(s) of interest the NIH CounterACT program. Applications propose research chemical threats are listed above not considered funding. research related opioid threats being proposed, NOT-NS-18-019 a description research supported the NIH CounterACT program. Application Submission Information Submit applications this initiative using following funding opportunity announcement through expiration date this notice. PAR-18-657 - Countermeasures Against Chemical Threats CounterACT) Research Centers Excellence U54 Clinical Trial Optional) notice applies the September 9, 2020 due date PAR-18-657. instructions the SF424 R&R) Application Guide the funding opportunity announcement used submissionmust followed, the following additions funding consideration, applicants must include NOT-NS-20-031” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Applications nonresponsive terms this NOSI be be considered the NOSI initiative. Inquiries Please direct inquiries the Scientific/Research, Peer Review, Financial/Grants Management contacts Section VII the listed funding opportunity announcements.

Pages